Crossmark

Adjudicating Mild Cognitive Impairment Due to Alzheimer's Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial

Crossref DOI link: https://doi.org/10.14283/jpad.2022.72

Published Print: 2022-10

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Schneider, Lon S.

Bennett, D.A.

Farlow, M.R.

Peskind, E.R.

Raskind, M.A.

Sano, M.

Stern, Y.

Haneline, S.

Welsh-Bohmer, K.A.

O'Neil, J.

Walter, R.

Maresca, S.

Culp, M.

Alexander, R.

Saunders, A.M.

Burns, D.K.

Chiang, C.
License Information

Text and Data Mining valid from 2022-10-01

Text and Data Mining valid from 2022-10-01

Version of Record valid from 2022-09-02
More Information

This article is maintained by: Elsevier

Article Title: Adjudicating Mild Cognitive Impairment Due to Alzheimer's Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial

Journal Title: The Journal of Prevention of Alzheimer's Disease

CrossRef DOI link to publisher maintained version: https://doi.org/10.14283/jpad.2022.72

Content Type: article

Copyright: Copyright © 2022 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS